law review1
TRANSCRIPT
-
7/27/2019 Law Review1
1/28
Pharmacy Law Review
Practice of PharmacyEducation Law: Articl e 137: 6801
Th e practice of th e p rofession of pharmacyis defined as th e administering, preparing,compounding, preserving, or thedispensing of drugs, medicines an dtherapeutic devices on the basis ofprescriptions or other legal authority, an dco llaborative drug therapy management inaccordance with th e provisions of sectionsixty-eight hundred one-a of this article.
PharmacyEducation Law: Article 137: 6802
Any place, other than a registered sto re, inwhich drugs, prescriptions or poisons arepossessed for th e pu rpose of compounding,preserving, dispensing or retailing, o r in
which drugs, prescriptions or poisons arecompo un d ed, preserved, dispensed orretailed, or in which such drugs,prescriptions or poisons ar e by advertisingor otherwi se offered for sale at retail.
5/22/201
Note
The authors ofthis material prepared thisinformation to pr ov id e accurate informationregarding NYS pharmacy law effective t he date ofthis pr esentat io n . Th e authors stronglyrecommend th e user refers to the original lawsources from where th i s informati on was tak ena nd use the following presentation as an adjunctto th ose materials. The presentation is only asummary an d does no t intend to cov er the entiresco pe of NYS pharma cy law .
AdministerEducation Law : Article 137 : 6802
"Ad minister", for the purpose of se ction sixty-eigh t hundr
patient specific ordu or o n p o ~ t i e . n rspecific rt:&imen prescribed or ordered by aphy sici couuey i nwhich t h~ imm u niut io n is .:utmil'l ist tri. fo r immuniutlons 10 prtovtnl innuenuor n e u m O < : o ~ : a ld i s t ~nd medications quii'Hi for t merctncy ln-.umtnl of; ~o~ p h y l a x i s ;l h h ~cou ncy- w ~r r thr im m unit.llhOil 10 be- .Miminist t rt d hu p o p u l . : ~ t io n of sevt nryfi Vt thou sa nd Ofltss . thrn tht lictn)'cd physician or ce rtifiednurse p rctitiontr may bt in ; ~n adjomi ng councy. Such d m i n m : r ; ~ t i o nshll ~l im i t ~to immun iz.ing &tnts o prtvtnt inftut n:u o r pnturnoa.c-al i s ~ . I I . H.11ndm e d i ~ ( i o ns requi r ed for t muge ncy t rratmtnl of .l.naphyluis_ o r
.11 pouitnt specific o rder plts cribed or o r de r ~by ph ysicia n or ~ n i t i r dnuT$rp r . ~ c h t M t n ~ rfor immut\iutions to p V ~ n t c ut ~ hcrpu zoster.
DEFINITIONS
-
7/27/2019 Law Review1
2/28
Definition of a Drug
Articles recognized in; Th e official USP Official Homeopathic Pharmacopeia of the US Official National Formulary Or any supp lement to any of the above
Articles intended for use in the diagnosis,cure, mitigation, treatment or preventionof disease in man or other animals
Definition of Food
Articles used for food o r drink for ma n orother anima ls
Chewing gu m Articles use d for components of any s uch
article
Label
A disp lay of written, printed or pictorial matter upon th eimmed iate containe r of any dr u g, device or cosmetic. Anyrequireme nt made by or under authority of hi s articlethat any word, statement, or other information appear o nth e lab el shall no t be considered to be compiled withunless such word, stateme nt or other informati on alsoappears on th e outside container or wrapper, if here beany, of t he retail package of su c h drug , dev ice or cosmet icor is easily legible through th e outside container orwrapper.
Immediat e conta ine r does not includ e package liners.
5/22 /2013
Definition of a Drug
Articles (o t h e r tha n food) i nt e nd ed toeffect the structure o r function of the bodyof ma n or other ani m als
Articles in tended for us e as a com pone n t ofarti cles in t he above clauses Not including devices
Cosmetic
Ar ticl es intended to be rubbed, poured,sp rinkl ed o r sprayed on, in t roduced in to o rotherwise appl ied to the human body forcleansin g, beautifying, promotingattractiveness, or altering the appearance.
Articles intended for use as a component ofan y such articles; except that the term shallno t include soap.
Labeli ng
All labels an d o ther written, printed, orpictorial matter
2
-
7/27/2019 Law Review1
3/28
GENERAL LAWS, RULES , AND REGULATIONS
REGUlATORY STRUCTURE AND
TERMS
Food, Drug and Cosmetic Act of
1938 Resulted f ro m 1937 sulfan il a mi de t ragedy
10 7 deaths caused by u se of di et h ylen e gyyco l(anti -freeze) in sulfan ilam id e e lixir
Incident propelled p assag e of th e 1938FD&CAc t
Dru gs mark eted prior to 19 38 we regr andf at hered
Du rham-Humphrey Amendment of
1951 Amen dment to th e FDCA Cr eated two catego ries of dru gs
Those t ha t required medical supervision :pres cripti on o r "leg e n d" drugs
Th o se that di d no t require medicalsupervis ion : "ove r- the-counter" orn onprescription drugs
5/22 /201
Pure Food and Drug Act
Signed in 1906 by Congress Proh ibi te d foods an d drugs that were
di st ribu ted through interstate co mmerce tobe adulterated or mi sbra nd ed Did no t require manufa cturers to li st
ingredien ts or directions Did no t regulate co smet ic p roducts or medical
devi ces
Food , Drug and Cosmetic Act of
1938 Any new dru gs m ust fi rs t be proven safe
w hen use d a ccor ding to the directions Requires labels includ e adequate di rectio ns
fo r use an d warn ing s abo ut habit fo rmingingredi en ts
App lies to cosme ti c products an d medicaldevices as well as food an d drugs
Durham-Humphrey Amendment of
1951 Required prescription drugs to include th e
lege nd on manufacturer 's label : "Caution: Federal law pr ohibit s d ispens in g
with out a pres cri pti on" {now "Rx o nl y")
Allowe d for oral prescriptions to bereduced to writing by th e pharmacist
Prescriber able to author ize refills
-
7/27/2019 Law Review1
4/28
Kefauver-Harris Amendment of1962
Resulted from thalidomide tra gedyof
1961
In th e US, was experimentally used in 1960FDA never gave final approval t o th e NDA.
Passed to ens ure greate r drug safety ANDeffective ness.
Medical Device Amendment of
1976 Class ification of devices according t o
sp ecific function Developed performance standards and pre
market approval requirements Manufac tu r er s must conform with GMP
st a n dards Mus t record an d report prop er information
Waxman -Hatch Amendment
Drug Price Competition an d Patent-T er mRestoration Act Made th e d ru g appr ov al pr ocess more effect ive
for generic drugs: must demonstr at e
"bioequivalence" to th e FDA Manufacturers of brand name products were
given specia l allowances as a resul t of goingthrough th e FDA appro va l pr o cess.
5/ 22/2013
Kefauver-Harris Amendment of
1962 Required a ll new dr ugs to be proven safe
AND effecti ve FDA is re spo ns ible fo r pr escr iption drug
advertising Require d i nf ormed conse nt fo r individuals
wh o were resea rch subj ects an d therepor ti ng of ADR's.
Creation of Good Ma nu facturing Pract ice(GM P)
Orphan Drug Act of 1983
Orphan drug Used to treat rare di seases
Tax an d licensing incentives tomanufac tu rers Made development of such drugs m ore
appealing (recover t he finances expended todevelop th e drug)
Prescript ion Drug Marketing Act of1987
Tighter re s t rictions o n the d ist r ibution ofpr esc ripti on samples an d products Ba nned th e sale, trade, or pu r chase of drug samp les Specifie d precise record-keepi ng requ irements fo r
drug samples (ie: storage ) Proh ibite d the resale of prescription drugs purchased
by hosp ita ls or health care facilit ies (the re were certainexceptions to this rule )
4
-
7/27/2019 Law Review1
5/28
FDA Modernization Act of 1997
On e major goal was to reenact th e 1992Prescr ip tion Drug Use r Fee Act (PDUFA) Major changes include:
Pediatric studies of drugs: manufacturers are given anadditiona l six months of marketing exclusivity if thedrug is accepted by th e FDA
States regulate pharmaceutical compounding an dpharmacies ar e exe mp t from GM P stan da r ds an d t heneed to submit new drug ap p licatio ns
Med icare Prescription Dru g Impr ovement,an d Modernization Act of 2003
The f ed e ral gove rnment con trols Medica r e Provide s seni ors and ind ividua ls with
disabilities with a pres cri ptio n drug benefit Part D
Prescri pt i on drug program Cos t to pati en t is in come -dependent
Medicare Part D
When a person enrolls , the premium and deductible are"foxed" from January 1 till December 31 of that calendar year.Co-Pays however may change if a d rug is moved to a differentcategory .
A pati ent may change plans only once yearly, between
October 15 through December 7, unless a special situationarises . Called Open Enrollment . Medi care Advantage Disenrollment Period: During this time
you can leave a Medicare Advantage plan and switch to anoriginal Medicar e plan . Runs from january 1 through February14.
s-Star Enrollment - A highly-rated insurance plan. Can switchonc e per year from December 8 - November 30.
5 /2 2 /201
FDA Moderni zation Act of 1997
Expediting study an d ap p rova l of Fast trackdrugs used to treat serious or life -threateningconditions
Elimination o f certain label requir em e n ts "Caution: Federal law prohibits dispensing wit hou t
a p r e sc r i p t i o n' ~ "Rx onl y" "Warning- May be habi t forming " has been
e liminated
Medicare Part D
Patients w ho are no t in a low-incomeca tegory pay a mo nt hly premium an d mustmeet an annual deductible. After they meetth e deductible: Th e plan will pay 75% of he annual drug costs until
th e "coverage gap" is reac hed During th e "co verage gap" , patient pay s all drug costs Following the "coverage gap ", the plan resumes
coverage
Me d icare Part D
"Any willing provider"- requires all prescri p tionbenefit programs must partici pa t e with anyp harm acy ag reeing to the terms an d condit ion s ofthe plan.
Pa t ients will no t be required to ge t their drugsvia mail-order an d can receive greater than 30 -day supplies of ch ronic medications at a localpharmacy
Vaccinations a re no w covered under Part D(except influenza, pneum ococcal, an d hepatitis}
-
7/27/2019 Law Review1
6/28
Medicare Part D
Contains a provision for MTM (MedicationTherapy Management) Pharmacists are able to receive payment from
Medi care if the pa tien t is enrolled in Part D Every benefit program sponsor must develop MTM
pr og rams for patients enduring significa nt drug cos t sfrom a number of chron ic conditions
MTM in cludes: medicat ion reviews , an t icoagulati o nmanag ement, immunizations , etc.
Helpful Medicare website:h ttp: // www. med icare .gov/
Poison P revention Packaging Act -1970
Intent of protecting children un d er 5 yearsfrom acc ident al poisonings
En forced by Co nsumer Produ ct SafetyCommission
Requires use of child- re sista nt containersfor packaging most OTC's, prescripti ondrugs , an d hazardo us h ouse ho ld products Dispense on ly once in resistant container s or
vials
Medications Affected
Acetaminophen- package containing> 1 g Diphenhydra min e - con tainin g >66 mg Ibupr ofen - conta ining 2: 1g
Loperamide - conta inin g> 0.045 mg Mouthwash- conta inin g .2:3 g of et hanol Lidocaine - conta inin g> 5 mg D ibuca in e - containi ng > 0 .5 mg
Naproxen - containing 2: 250 mg
5/22/2 0 13
Poison Prevention Packaging ActREGULATORY STRUC TURE AND
TERMS
Medications Affected
Asp irin Methyl salicylate- liquid prod ucts
conta ining >5% by weight unless packagedin pressurized spray cont ainers
Contro ll ed substances Prescr ipti on drugs - or a l dosage forms I ron- all non-i n jectab le drug products an d
dietary supplements contain ing 2:_250 mg of
elementa l iron pe r package
Medications Affected
Ketoprofen - containing 2:50 mg Fluoride - containing >50 mg of elemental
fluoride an d o.s % fluoride Minoxidil - containing >14 mg Nonprescription products - an y oral
product th at cont ains any active ingredientthat was previously available byprescription
6
-
7/27/2019 Law Review1
7/28
Child Res is tant Con t ainers
Des igne d to be sign ificantly hard forch ildre n
-
7/27/2019 Law Review1
8/28
Exceptions
Pancrelipase preparatio ns (tablet , capsule, pow der forms )
Prednisone tab lets: ~ 1 05 mg per pa c kage Methylprednisolone tablets: ~ 8 4mg per package Oral contraceptives: adm inist ered in manuf ac tur er 's
mnem onic dispenser Ho rmone replacement products- rely so le ly on the
activity of o ne o r more progest ogens or estrogens
Drug Approval Process
REGULATORY STRUCTURE AND
TERMS
In vestigational New DrugApplication
First application form a spo n so r mu stsubmit to th e FDA before administration tohuman s
Pr otects th e righ ts an d safety of hu m an testsubje cts Inclu de proo f of preclinical te st in g on animals
FDA ha s 30 days to decide whether th einvestigational drug is suitable for t es ting
5/22/2013
Anti-Tampering Act of 1982
Requires tampe r evide nt packaging be u sedfor select OTC products a nd cosmetics
Product has an indi cator or barri er to en try If he seal is br oke n , so me visib le ev id en ce of
entry w ill be evi dent
Product label mu st state t ha t it is a tamper -ev id en t pa ck age an d how to know if thepac kage h as been ta mpered wi t h
New Drug
Drug n ot recog niz ed among expert s as sa fean d effec t ive for use under th e conditi on srecomm e nded in the drug's lab elin g
Cl inical Trials - Phase I
Sma ll gr ou p of hea lthy patients Ultimate goal is to eva luate toxicological,
pha rm acological a nd pharmacok ineticdata , as well as assess safety i n hu ma ns
8
-
7/27/2019 Law Review1
9/28
Clinical Trials- Phase II
Larger group of patients ( ~ 1 0 0 )that havethe disease or sy mptoms
Primarily con ce rned with determininguse fuln ess in prevent in g or treating th edisease
Treatment Investigational NewDrugs
Allows th e administration of anin vestigatio nal new drug in those patientsw ho ar e no t enro lled in th e drug 's clini ca ltrial Pa ti en ts ar e at a life -threatening stage of heir
illness to w hi ch th ere is pres e ntly no cur e ordrugs ap pro ved to treat th e condition have no tbeen effect ive
Clinical Trials - Phase IV
Occ urs after drug pr o duct is mark eted Obta in additiona l data of drug's safety and
effec tiveness
Determine new uses or abuses
Hea lth care profession als ar e encoura ge d torepo rt any probl em s ex per ienced with th edrug 's u se (adverse ef fects)
FDA can withdraw drug based on datacollected
5/22/201
Clinical Tria ls- Phase Ill
Large group of patients, u sually in a clini calse t ti n g
Provide s additional evidence of theeffectiveness and more information onadverse reactions
Provides additional information onoptimum dosing
New Drug Application
Requ est for appro val for marketi ng On ce ap proved, manufacturer may mark et
product
Co mp l e t e evaluation of sa fety an d efficacy FDA gene rall y rev iews NDA for at lea st 180
days and allows in t e rested indi vidual s toview an d comment on the app lication
Fast Track Approval
App rove d by th e Sec r et ary of HHS Allows for th e expedited approval of a
pot ential new drug if that product is: intended to treat a seriou s oflife threatening
conditi on AND addresses a n un m et m ed ica l ne ed
Approva l also conditioned on po st-mark et ing studies to ve r ify and describeth e drug 's benefit
-
7/27/2019 Law Review1
10/28
Abbreviated Ne w Drug Application
Requires less data than NDA but it doesrequire proof that th e new drug'spharmacokinetic properties, bioavailabilityan d clinical activity is similar to th eoriginal developer's product
FDA Classification fo r Ne w Drugs
Type P (priority) No other effective drugs available
Possess significant advantage compared tocurrently marketed drugs
Type S (standard) Similar to other drugs on th e market
Further Classification
TypeAA Drug with potential
use for AIDS or HIVrelated disease
Type E
Type F Drug that has been
placed on hold untilsubmitted data ha sbeen further validated
Drug for a life- Type Nthreatening or severely Drug being considereddebilitating disease for O TC status
Type V Drug being considered
for "orphan drug"status
5/22/2013
Supplemental Ne w Drug
Application Applies to manufacturers who originally
filed an NDA Utilized to adopt changes for an existing
drug product ranging from production tolabeling
Eliminates th e need to file a new NDA
Chemical Classification
Type1 New molecular
structure
Type 2 New derivative of a
molecular structurealready approved in US
Type 3 New formulation of a
drug already marketedin US
Type 4 New co m bination of
two or more drugs
Type 5 Drug is being
manufactured by a newcompany
Type 6 New therapeut ic
indication for a drugalready approved
CONSIDERATIONS FOR
MARKETED DRUG PRODUCTS
10
-
7/27/2019 Law Review1
11/28
-
7/27/2019 Law Review1
12/28
Misbranding
Labeling is fal se or misleading Labeling is mis s ing either name or l oc at i on
of manuf ac t ur er / distributor
Label does no t co n tain a wo rd , state ment ,or other information required by lawdisp laye d in a prom in en t , rea d able manner
Label does no t include th e estab lishedna m e of t he active drug
Misbranding
Labe l has inadequat e direc tions fo r use fornonprescription drugs or does not include appropriatewa rni ngs req uir ed to protec t th ose using th e medicationo r pa ckaging
Label is n ot in accordance w ith USP/NF specifications Labe l offe rs the sale of th e dr ug und er th e nam e of
a nother drug Fai lure to pac kage d rug according to Poison Pr evention
Pac kag ing Act Does not po sses s t he state me n t, ''Wa rning-May be h abit
forming " on narc otic or hypnoti c substances
Manufacturer Drug Label
Na m e a nd ad d ress ofm a nu f actu re r packer distributor
Esta bli she d name of drug
Ne t quantity Weight of each ac t ive in gre dient cont ained
in ea ch dos ag e unit Federa l legend - "R x Only"
5/22 /2013
Misbranding
Label do es no t have each active ingr edi en tidentified Labe l do es no t sta t e "Rx only" if a
pr esc ripti o n drug Labe l does no t contain a precautionary
st atement concern ing a d rug su bject todeteriorati on
Labe l is m iss in g quan tity of cont ain er'sco ntent
Product Labeling
The term "labe l" refers to wr itt en , printed,or gra phic matt er ap pearin g on th eimmediate con tain er of a drug produ ct If there is a n o ut side package , any word,
sta te m ent, or oth er inform at ion present on theinner containe r m u st also appea r on th eo ut side package
"Labelin g" refe rs t o th e ab ove, as well asan y a ccom panyin g wri tten, printed orgra ph ic matter (i.e. patient package insert)
Manufacturer Drug Label
If not t aken o raUy, th e s pecific ro ut e ofadministration
Speci al storage directions if ap plicabl e
Manufacturer 's contro l o r lo t number Expi ra tion date established by
manufacturer
State m en t dire ct ed to pharm ac is tspecify ing type of co nt ainer to be used indispensing
12
-
7/27/2019 Law Review1
13/28
Special Label Warnings
FD&C Yellow No.5( artrazine)
Aspartame Sulfite s Minera l oil Wintergreen Oil Sod ium Phosphates
Isoproterenolinha lation produ cts
Ipecac syrup Ph enac et in Salicylates (includin g
aspirin) Alcohol warning
Package Insert
Description (c hemical s tructur e, solubility,etc .)
Cl inical pharmacology Indicati ons, usage Warni ngs , pre ca utions an d
co ntraindications Adverse reactions
Patient Package Inserts
Regulation requ iring information t o beprovided to patient concerning amedi cation's Us e Potent ial Risks
Provided as a leaflet written in lay languag e Considered part of FDA-regulated product
labeling
5/22/201
Package Insert
Manufacturer required to provide inprescription drug packages In f o rm at ion contained within insert must
be app rov ed by the FDA For informational purpo ses only
Package Insert
Drug abuse an d dependence Symptoms an d treatment of overdose Reco mmended dosage an d administration Available dosage forms Most recent labe l revi s ion date
Patient Package Inserts
Applies to all physicians , communitypharmacists, and hospita l pharmacists whod ispens e In acute car e ho spitals , regulation exempts the
provision of a PPI each time th e drug isdispensed
PPI must be provided prior to theadminis tr ation of th e first dose and every 30days thereafter
-
7/27/2019 Law Review1
14/28
Medication Guides
Manufacturers provide Medication Guidesfor certain prescription drugs that p ose aseri ous a nd signifi cant public hea lthco ncern Must obtain FDA a pp rova l of th e Me d Guide
an d supply sufficient copies to pharmacies
Applies to both new an d refill p rescr ipti ons
Pregnancy Warnings
Category A Have been adequ a te , well co ntrolled studies in
pregnant wo me n that de m onstrat e n o risk tothe fetus d urin g a ll tr im es ters o f pr e gnan cy
Ca teg ory B Adequat e, we ll co ntrolled st udi es have not
been conduct ed in pregn an t wom e n . An im a lrepro du ctive stud ie s h ave failed todemonstrate fetal risk.
Pregnancy Warnings
CategoryX Co n tr aind icat ed in pregnant women St u dies in an i m a ls o r reports in pr eg nant
wo m en , indicate that th e risk of d amage
ca used b y th e d rug clearly outweighs anyposs ibl e b en efit
5/22 /2013
Medication Guide s
FDA requires MedGuides when: Patient labe lin g co uld prevent serio us adve rse
effec t s The product has ser iou s risks rel ativ e to
benefits
Patient adherence to di rectio ns is c ru cial
Prescriber m ay req ue st a Me d Guide not beprovided to a part icula r patient
Pregnancy Warnings
Category C Safe ty of the drug durin g hu m an pregnancy
has no t bee n determined . Animal studies areei ther positive for feta l risk or ha ve no t beencondu cted.
Category D Pos iti ve ev ide nce of ri sk to hu m an fetus mainly
based up on adverse reaction data
Un it Dose Packaging and labeling
In fo rmati o n to be includ ed o n eac h unit-d ose package: Generic name and trad e name, if applicabl ( Q uantity of active drug
If mo r e than one , t he number of dosing units . Na m e an d place o fbus in ess o f manufacturer /pac ker /distributor
Lot o r co n trol number
Expiration date
'"Warni ng: May b e hab it form ing"' if app l icable , the properco n trolled substa n ce symbo l , in addition t o a n y r equir ed info .
O th er appropriate information if needed (ie : fo r a re cognized drug r ~f r i g e r a t e, "protect !Tom light, etc .
14
-
7/27/2019 Law Review1
15/28
Bar-Coding
FDA requires pharmaceutical companies toba r code all drug products supplied tohospitals (however hospitals are notrequired to utilize them) Prescription , biologicals , nonpres crip tion Single-unit containers used for unit-dosing Not physician samples
Bar code must contain product's NDC Considered to be part of produc t label
Subject to GMP
MedWatch Program
Enhances the effectiveness of postmarketing surveillance
Quickly identifies major he alth concerns Increase awareness of drug-and device -
induced disease
Clarify what shou ld be reported
Make it easier to report problems Pr o v id e regular feedback to the health ca re
community
Drug Recalls
Class I May ca use serious adverse health consequences,
including death Includes stock in pharmac ies and notification of
patients Class II
May cause temporary or reve rsib le effects Usually includes stocks in pharmacies
Class IIJ
Un like ly to cause any adverse he a lth cons equence
5/22/2013
REPORTING INITIATIVES
VAERS
Co -sponsored by CDC and FDA Vaccine Adverse Event Repor ting System
Surveillance system to report any eventconcerning th e ad mini stration of vaccineslicen se d fo r u se in th e US .
Compounding vs. Manufacturing
Due to the in creasing number of drugproducts compoun d ed by manufacturers,less compou ndin g is performed inpharmacies .
The main qu estio n is "When doesprescr iption compounding be co memanufacturing ?"
Refer to the FDA Compliance Policy Guideof 1992 to address this issue
-
7/27/2019 Law Review1
16/28
Compounding vs. Manufacturing
The quantity prep ared is rea so nable for filling eitherex isting presc ripti ons or anticipa ted o rder s based onp resc rib ing hab its of loca l prescr ibers.
Dosage forms comp ou nded a re not being prov ided or soldto ot her pharm aci es o r th ird parties.
Wha t is com pounded is no t cu rr entl y availabl e from am an ufactu rer/su pplie r
A pharm acy can say they specia li ze in prescriptioncomp oun d ing bu t CANNOT specify a specifi c prod uct
The ph armacy mu st lim it its in terstate distrib u tion ofco m pounded products to n ot more than s% of ts tota lprescr ip t ion vo lum e.
Repacking
Can be done by a pharm acis t, or anunlic ense d pe r so n un d e r the sup erv ision ofa regi st e red pharmac ist.
Labels o n repa cke d dr u gs shall bearsuffi cient in f o for p rope r ID an d safety .
Spec ific records mu s t b e ma in tained.
Recor ds must b e maint a in ed for 5 yearsan d mu s t be readi ly ava il able
NYS Organizati onal St ru ct ur e
REGULATORY STRUCTURE AN D
TERMS
5/22/2013
Expirations fo r Compounds
Always use stabili ty info rm atio n available If n o in format ion is avai lab le:
For no n aq ueous liquid s an d solids - no t moret han 25 % of he time remaining on th eco mm erci al produ ct or a max o f6 m on t hswh ich ever is le ss
Aq ueo us so lution s made fr om so lids - 14 dayswhe n store d at a co ld temp eratu re
Al l others : th e du ra t io n of thera py, n ot moreth a n 3o da ys
Repacking
Record keepin g in cl udes:N amto ~ n d st r encth o fthto dru gN.amto oftht' m oulu fact urto r a nd dist ribu tor (if diff f renl )Manuf act ure-r lot num b e r
Qua ntiry of each coma iMrNumbero fu nits ~ ~ r . d
Oa t t f t -t o~ c l d n E ~ C p i r a t i o nda tin gS ig na t u ~of p erso n p to rf o r mi n& th e re.pac king
Slaru.rure oft he ph
-
7/27/2019 Law Review1
17/28
State Education D e partmentEdu cation Law : Article 130 Subarticle 2: 6507
A dm in iste rs t he adm iss ion t o an d pra cticeof the p ro fessions Estab lish st a n da rds fo r pr e-pro fession a l
and p rof essi ona l e du cat i on , ex p erienc e a ndlice n sing examinati o n s
Reg is ter o r app rov e edu cat io n p ro gra ms Iss ue lice nses, reg istrat io ns, an d limit ed
permits to qualified appli can ts
State Board of Pharma cyEdu ca tio n Law: Arti cle 13 7: 6 804
Board co mp ose d of no t less t h a n 9 p h armaci sts licensed in th e
st at e fo r at least 5 ye a rs AN D
at lea st 2 pub lic re pr esen ta t ives
Exec u tive Sec re ta ry App oi n t ed by th e rege n ts on rec om m end ati on
of he co mm ission e r Licen se d in state for at least 5 yea rs
To PracticeEdu ca tion Law: Art icle 130 Subartic le 1: 65 02
A licen se is vali d durin g life o f the ho ld erun less revoked , an n u lled o r suspe n d ed byth e b oa r d of rege nt s
Must reg ister w it h e d ucat i on departm entt o p racti ce
5 /22 /201
State Boa rdsEducation Law : Article 130 S ub ar ticle 2: 6508
Ap po int ed by t he Boa rd of Reg en t s Assis t th e board of rege n ts and st a t e e du ca t ion
depa rt m en t on matte rs of pr o fess ion al licen sin g,pr a cti ce a nd co ndu ct
Pr e par e ex am in atio ns an d assist the depa rtmentin o th er licen sin g m a tter s as pr e sc ribed by theboa r d of regents
Co nduct di scip lin ary p rocee d ing s an d a ssist ino ther professi o na l co ndu ct m atte rs
Revi ew ap pli cat i on s for l ice nsure
State Board of PharmacyEducation Law : Article 13 7: 6804
Reg ulat e t h e pr ac tice o f p harmac y an d th e emplo ymen t o fintern s a nd em ployees i n p ha rma cies,
Reg u late an d co nt ro l t he sale , dis tr ibut ion, ch ar ac te r an dstandar d of dr u gs, poisons , cos m etics, devices an d n ewd rugs ,
Em pl oy inspectors a nd chemi sts , P rev ent th e sa le o r d is tri buti o n of such drugs , po iso ns,
cos metics , de vices an d new dr u gs as d o n ot conf or m toth e p rov is io ns of this ar t icle or of t h e pu blic heal t h law,
In vesti ga te all ege d violatio ns Iss ue lim ited p e rmits o r regi st ra tio ns .
Change o f Informat ionEducat ion Law: Art icle 130 Sub art icle 1: 650 2
A ddre ss or Name c hange Education law req u ires n o tifi cat io n with in 30
days
1
-
7/27/2019 Law Review1
18/28
Continuing Educat ionEducati on La w : A rt icle 137: 6 82 7
Re gulat io n s of th e Co mm issio ne r : Pa rt 63 : Pharmacy : 63. 7
Must regi ste r triennially an d comp ly withcontinu ing ed ucation req uir eme nt s
Complete a m inimum of 45 hours No more th a n 22 hours shall cons is t of self-
stud y courses At least 3 hours must b e re lated to m edication
er r ors
Recent graduat es no longer exempt! Exempt on ly if no t engaged in practice
Continuing Education
Collaborati ve Drug Therap y Man age m en t At least 5 hours of formal cont inui ng education
a cce ptab le to th e dep artm e nt in th e area o r a reas ofpr act ice generall y rela ted to any co lla borati ve drugther apy management pr ot o co ls to whi c h th ephar ma cis t ma y be subj ec t
Continuing Education -Record keeping
Must record th e following informat ion foreach co ur se taken: Titl e Number of hours Sp onsor 's name Verification Date an d location
Must be maintain ed for 6 years from th edate co mpl eted
5/22/2013
Continuing Education
"accep table fo rmal c on ti nuing ed ucat ion" - formal co urses of
learmn g which con trib ute to p rofe ssional pra ctice in pha rmacyand wh1 ch meet th e standard s pr escribed by regul ati ons of thecom mi ssion er T ec hn iqu es to reduce m edi ca tio n and pre sc ripdoo errors Pharm acology of new a nd deve lopin g dru gs; d ru g int erac t ions Pub lic hea lth issu es Infec t ion co ntro l Ste r ile p rod ucts Lega l an d reg u lat ory issu ts Pa ti en t coun se lin g Ch ild abuse reponi ng O th e r topi c s tha t co n tr ibu te t o rh e p r o f es si o n ~l pra c tice o f ph a rmacy O t h ~r matte rs o f h e~ l t h car e , law , an d e t hi cs th at co ntr ibu te fo t he
public 's h ealth an d wel fa re .
Continuing Education
Sp onsors m ust be approved American Council on Pharma ceu t ical
Educati on College s, universities, other degree granting
institutions registered by th e Educati onDepartment or accredit ed by an equi valentagency
Sponsor s approved di r ectly by the Departm ent
Continuing Education
One CE cred it equals: 6o minutes or
One contact hour 0 .1 CEU
O ne sem ester hour = 15 conta ct hours= 1.5CEUs = 15 credi ts
On e quarter hour = 1 0 conta ct hou rs = 1. 0CEUs = 10 credit hou rs
18
-
7/27/2019 Law Review1
19/28
Professional MisconductEducation Law : Article 130 Sub article 3: 6509 - 6511
Obtaining license fraudulently Pra cti cing frau dulentl y, beyond scope of
prac tice, with gross in co mpetenc e, withgross neglig e nce
Practicing w hil e influ e nc ed
Ha bitual u ser of drugs
Unp rofes sional Conduct for HealthProfes siona ls
Rules o f the Board o f Regents : Part 29: 29 .2
Aban donin g or neg lect ing a patient undera nd in need of immediate professional carewithout makin g arrang e ments
Abandoning professiona l e m ploy m en twitho ut reaso nabl e notic e
Willf ull y hara ssin g, ab u s ing or intim idatinga pa t ie nt e it h er ph ys ica lly or verba lly
Fa iling to m aintain a pa t ien t recordacc urately reflect ing treatme nt
Unprofessional Conduct for HealthProfessionals
Orde rin g excess ive tests , treatments, or useof trea tm ent facilities n ot wa r ran ted byco n d iti on
Failing to wear an id ent ificatio n b adge
5/22 /2 0 1
Professional Misconduct
Being convi cted of a cr ime Refusin g to p rovid e service s du e to a
person's race, creed, co lo r , or nat io nalor igi n
Allowin g a n un licensed pers on to performprofessi onal activities
Practic ing wi th a suspe n ded license, fa ilingto regi ste r or n otify of name / addressch ange
Unprofessional Conduct for HealthProfe ssionals
Usi ng the wo rd "Doctor" in offe ringprofessional services wi t hou t alsoind icating profession
Faili ng to exercise approp riat e supervisionove r persons over those who are requiredto be superv ised
Guaranteeing sa t isfactio n or a cure w illresul t from performance of profess ionalserv ices
Unprofessional Conduct fo rPharmacists
Rul es of the Board of Rege nts : Part 29: 29.2
Not following reg ul ations for wr ittenprescriptions, labels , medication orde rs ,oral prescr iptio ns , d ispensing aprescript ion, r efill s, subst itu tio ns
Fai lu re to number prescriptions prop erly Failur e to m ain tain appropria te records Fail ur e to mak e pr escri ption d ru g list
ava ilab le
1
-
7/27/2019 Law Review1
20/28
Unprofessional Conduct fo rPha rma cists
P lacin g in stock a prescriptioncompounded or dispensed after returnedby patient
Selling adul te r ated or m isb randed drugs Selling outdated or improperly stored
drugs
Registrations for EstablishmentsEducati o n Law: Articl e 137 :6808
Required of all individuals , partnerships , orcor poratio ns who possess drugs,prescriptions or poisons for th e purpose ofcomp oun ding , dispe nsin g, retailing,who lesaling, or manufactur ing , or whooffer drugs, pr e scriptions or poisons fo rsale at retail or wholesale
Pharmacy as a Department
Shall be p hys ically separat ed from th e restof the estab lishment Access to de p artme nt is no t avai lable when
ther e is no pharmacist present
Identification of the area shall b e restrictedto th e area licensed by the department aspharmacy
5/22/2013
RULES OF THE PHARMACY
Registrations fo r Establis hmentsEducation Law: Article 137:6808
Regulations o f h ~ Comm ission er: Part 63: 6 3.6 a
Separate regi s tratio n required for each ph armacy An appli catio n for endo rse me nt to another address
shall be m a de no le ss than 30 d ays p ri o r to e xpe c te ddate of r e loc at i o n
Must be consp icuou sly disp layed at all tim es Names of owners con spi cuously di s pl a yed up on th e
e xter ior o f th e establi shment
If ow ne r is n ot a ph a rmacist , mu st bea r na m e o fsupervi sin g pharmaci st
Pharmacy RequirementsRegu lat ion s of th e Comm issioner : Part 63 : 63.6 b
To secure an d retain registration , need atlea st the following : weig hin g device sensitive to 6 mg; metric weights , if ne e de d
devices capable of measuring volumes from 0 .1ml to soo ml; and
a mortar an d pestle .
20
-
7/27/2019 Law Review1
21/28
Pha rmacy Requi remen t s
Not less t h an 3 0 0 sq u are feet In clude a m an u factur in g, co m p ou n ding a rea of
no t less than 1 00 feet
Equi pp ed wi th storag e faci lit ies p rovidi ngfor safe storage of dr u gs
Ad equate heating, ve n t ilation an d li ghting H ot an d co ld runn i ng water
Phar ma cy Requir e ments
Ph a rm acy as a Departm en t Enclo sed permane nt l y by a pa r t it io n a t least
9'6" unless t he ce ilin g is less than 9'6" Th e partition must be from floor to ceiling
Wh e n no t opened d urin g a ll hours m aintainedby th e esta blishm e n t, a n exterio r sign shouldbe pos t ed clea rly in d icat ing t h e h our s '
Limited Pharma cy Re gistration
Department ma y wa ive any requi rementspertain ing to: Full -time operatio n M inim um equi pm ent
Minimu m space an d waitin g ar ea
5/22/ 20 1
Pharmacy Requi rements
Ref r igerator equ ipped with thermometer(2c-sC)
Co p ies of the laws, ru les and regu lationsgoverni ng the practice of NYS
O ther up -to -date refe rence booksnecessary to carry on practice
Limite d Pha rmac y Reg ist ratio nEducation Law: Arti cle 137:6808
Phar macy within a hospital, nurs ing homeo r extended care faci li ty does no t meet allre qu i reme nts for reg ist ration But can provide high standard of patient safety
wi th good patient care
Pha rm aceutical services shall be li m ited toth e pa t ien ts registe red f or trea t me nt by theva r io us fac ilites
Nonr esi den t Es t a blishm e n t sEducation Law: Article 137 :6808-b
Reg u lations of the Commis s ione r: Part 63 Pharmacy : 63.8
Any pharmacy, m anu facturer, orwh olesaler locate d outs ide of the NYS thatships , mails, or de livers prescr ipt iondr u gs /dev ices to o th er establ ishmen ts,au th or ized p resc rib ers resid ing in NY .
Shall in clude in t e rn et pharmacies
2
-
7/27/2019 Law Review1
22/28
Nonresident Establishments
Agent o f r ec o rd A designee residing in NY for service of proce ss
Must pr o v id e a toll free number that isavailable during normal business hours and a tleast 40 hours pe r week Enable comm un ication between a pat ient and a
pharmaci st Number mus t be placed on a label affixed to
each drug or devi ce container
Drug Retail Price List
Pharmacy Requirements-RadioactivePart 63: 63 .6 b (6)
Need to m e e t requirements as s tated in 10NYCRR P a r t 16 (med ica l and a cademicfacilities) o r 12 NYCRR Par t 38 (commercialfacilities)
Must ha ve appropr ia te lice ns e issu ed byNYS Dept. o f Health or Labor
Pharmacy Requirements-Radioactive
Shall also be equipped with th e following: Laminar flow hood Dose calibr ato r Exhaust hood and folter system Chromatography apparatus Apparatu s or mate rials for the dete rmination of pH Single-channel and /or multi channel scintill ation
detect ion system Microsco pe
5/22/2013
Nonresident Establishments
Registration requirements Licensed an d registered in state of origin Maintain records in readily retrievable form
Supply information upon r equest Co mpl y w it h all statutory an d regulato ry
requir emen ts of residing stat e for prescriptiondrugs or devi ces shipped, mailed or deliver edinto NY
For CS must follow federal and NY law
Pharmacy Requirements -Radioactive
O n e pharmacist should be presen t a t allhours when th e pharmacy is openm ee ting:
Minimal standards o f raining a nd experience
Submitted to th e state board ei t he r : Certification as Nuclear Pharmacists by BPS Completion of minimum 2 0 0 contac t hours of
didactic instru ction in nuclear pharma cy and aminimum of soo hour s training unde r thesupervision of a board certified nuclear pharmacistin a cert ified nuclear residen cy/t raining program
Pharmacy ConductEdu cation Law: Ar ti cle 137 :6808
Every owne r o f a pharmacy or everypharmacist in charge o f a pharmacy sh a llbe responsible fo r the p roper conduc t ofthis pharmacy.
A pharmacist m u s t b e present a t al l hoursw h e n op e n
O ne pharmacy per supervising pharma c is t
22
-
7/27/2019 Law Review1
23/28
Supervis ing Pharmac istRules of the Board of Regents Part 29: 29 .7a (10)
Ed uca tion Law: Article 137: 6808
Each registered pharmacy must be unde rthe supervision of a registered phar mac ist
The SP is responsible for ensuringcomp li a n ce of all rules an d regu lations
Oversees all employees of the pharmacy May no t as sign responsibility to others Must have active ro le in phar m acy
Change of Supervisor
The owner shall notify the department withthe name of th e rep lacement pharmacist
Apply for an amended registration Attac h to origina l registration
Both owner an d supervising pharmacistshall be responsible for carrying this ou t
Must be done within 7 days of change
Phar m a cy Intern
May practic e as a pharmacist under theimmediate personal supervision of apharmacist When a prescript ion is dispensed by an intern,
must have both intern 's and pharma cist'sinitials
5/2 2/201
Supervising Pharmac ist
Must practice at p harm ac y full ti m e At lea st 30 hours a week
If pharmacy is open less than 30 hours aweek : Must be pr es en t fo r th e majority of hours
Pharmacy InternEducation Law : Article 137:6806
Lim ited permit auth orizi ng the practice ofpharmacy unde r th e immediate an dpersonal supervision of a registeredpharmacist Must have co mplet ed first year of prof ession al
study OR A gr a duate of a pharmacy prog r a m wh o is
engaged in meetin g th e experiencerequir ements or whose application is pendin g
Expiration dat e of 5 years
Pre cep t or PharmacistPart 63: 63.2a (3A)
Must have practiced at least one year
Cannot supervise no more than one fulltime in tern or two part- t ime interns
In pharmacy training interns , one internfor each sooo prescriptions disp ensedannua lly
2
-
7/27/2019 Law Review1
24/28
Unlicensed Assi stantsPart 29: 29 .7a ( 21)
Does no t includ e interns, staff no t directlyrelated to th e filling of pr escr iptio n s
Up to two unlicensed persons may assist apharmacist
Unl icensed Assistants- AllowedTo ...
Count dosage units o f drugs Place d os age units of drugs in appropriate
conta iners Affix th e prescription lab e l to th e contai ners Prepare manual records of di spe nsin g for th e
signa tu re or initia ls o f th e p h armacist Hand or deliver comp leted pr escriptio ns to th e
pa t ien t or th e person a u thorized to ac t on behalfof he pat ien t
Unlice nsed Assistants- NotAllowed To ..
Measure, weigh, co mp o und or mixin gredients
Sign or initi a l an y record of dispe nsi ngreq ui re d to be maintained by law
Counse l pa t ients Perform any other function inv olvi ng th e
exer cise of professio n al judgment
5/22/2013
Unlicensed Assistants- AllowedTo ..
Rece ive written or elec tr o nicall y t r ansm ittedprescriptions , except that in th e case ofelectron ically transmitted p rescriptions
Type p rescrip t io n la bel s Key prescription data for e nt ry in to a computer
generated file or r et riev in g prescription data fromth e file
Get drugs from stock an d returning them to stoc k Get prescripti on files an d other manual records
from st orage an d lo cating prescript ions;
Unlicensed Assistants- NotAllowed To . ..
Receive oral p re sc rip tio n s fro m prescribers Interp re t an d eva luate a pr escr ipt ion for
confo rman c e with legal requirements,au then tici ty, accuracy an d interaction ofth e prescribed drug with ot her know nprescr ibe d an d over - the-counte r drugs
Make determinat io ns of the th erape uticequ ivalency as suc h determi na tio ns ap p lyto ge n er ic s ubsti tu ti on
Reporting Requi re men ts
Transfer of ow ners hi p At leas t 6 weeks pr ior to proposed da t e
Change in corporate offic er s an d / orprinc ipal stockho lders Not ifY within 30 days
Fire, flo od , disast er W ithin 48 hours of damage
Chang e in Supervisor Within 7 da ys of an y change
24
-
7/27/2019 Law Review1
25/28
Reporting Requirements
Change of location Not less than 30 days prior to th e expecte ddate or r elocat ion
Renov at ions Should be reported prior t o an y renovations
Change in corporate name Notify prior to u se o f any ne w nam e
Drug Retail Price ListEducation Law: Article 137:6826
Regulations of he Commissioner: Part 63, Pharmacy:63.6(9)
Sign posted no t ifyi ng patients of the ava ilability ofa drug re tail price list "Drug Retail Price List Availabl e Upon Request" in
bold, block letters of at least on e inch in height Drugs on list provided by the board of pharmacy 15 0 most frequently prescribed drugs
Updated week ly Conta in advisory statement
Need to tell heal th care practitioner and pharmac istabout medications/avoidance of harmful int eractio ns
Prescriptive Author ityPRESCRIPTIONS
5/22 /201
Reporting Requirements
Tem po ra ry closing No ti fy prior to any su c h closing as well as priorto reopening
Sale of drugs at Auction Must be not ified at le as t seven days prior to
auction
Drug Retail Price Li st
Retail p rice means the actual price to bepaid
We b- based pharmacies must post Notice of th e availability
Provide a toll-free number
Ma il -order pharmacies Provide a printed notice with each d elivery
infor m ing the patient abou t t h e availabilty
Provide a t oll -fr ee number
Prescription
A prescription shall be issued by apractitioner fo r legitimate medical purposesin good faith an d in the course of his or her
professio nal prac tice only.
2
-
7/27/2019 Law Review1
26/28
Who Can Prescribe?
Tradi ti ona l Prescribers Doctor of Me di cine (M.D.) Doctor o f Osteopa th y (D.O.) Doc to r of Den ta l Surgery ( D.D.S.) Doctor of Dent a l Medicin e (D.D.M.) Doctor of Podiatric Medicine (D .P.M.)
Doctor of Ve t erinary Me di cin e (D.V.M .)
Midwife
Ma n age m ent of n ormal p re gn a nci es, c hil dbirth and postpartum care as we ll asprim ary preventive reproductive hea lthcare of es se ntiall y heal t hy women
Includ e n ewborn eva lu ation, r esuscitationand referral for infan ts
Midwife
May pre scr ib e an d admini ster drugs ,immunizing agents, diagnostic test s a ndo rde r lab tests limited to the practice Include s co nt r olled substances
Register with stat e License numb e r begins wit h F + 6 digi ts
Own prescription blanks
5 / 22/2013
Who Can Prescribe?
Under certa in c onditi o ns : Midwife Nur se p rac titi one r (NP) Ce rti fied o ptome tris t
Registered ph ysici an assis t an t (R. P.A.)
Those not allowed: Doctor of Op to m e try (O.D .) (u n less cert ified) Doctor of Chiroparacti c Medicine (D.C.) Op ti cian o r O phth a lmi c di spenser
Midwife
Midwifery sha ll be practiced in accordancew it h a written agreement between th emidwife : A lice nse d ph ys ician w ho is board certified as
anOB / GYN
A licensed physician wh o p ractices obstetricsa nd h as o bs t etric privileges a t a hospi ta l
A hospital th a t provides obstetrics th r oug h alic en sed ph ys ician
Nurse Practitioners
Obtain a certificate from th e departmentup on su ccess full y co mpletin g a programincluding an appropriate pharmacologycomponent, or its equivalent
Must ha ve collaboration wit h a physician Must be ke pt on file with th e p hysicia n , with
t he State Edu ca tion Department an d at theNP's p ractice site
26
-
7/27/2019 Law Review1
27/28
Nurse Practitioners
May p rescrib e for contr olled substances Must ha ve D EA n umber
Li ce nse regi st ration will beg in with an F + 6digits Fi rs t two di gi ts represent spec ial ty area
May have own prescripti o n blank s wi thn am e an d desig nation im printe d
Optometrist
Must be certified by NYS Edu c ationDepart m ent
Those wh o are cert ifi ed ca n b e identified byletter pr eced in g th eir license num be r: T = diagn ostic age nt s U = Phase O ne agents
V = an y a ge nt
Own pres cr ip tion blan k
Optometrist - Phase On e
Completed at least 30 0hours of dinicalt:raining inthe diagnos is, creatment andman ageme nt of patien tswith oc ular disease ot herthan glaucoma and ocu lar
hyp ertension Successfu lly pa ssed th e
t:reaonent and managementof ocular diseases po rt ion ofthe Nat iona l Board ofExam iners in Optometry test
Antibiotics Decong estants /anti
a ll ergenics NSAIDs Ste roidal anti -
inflam matories Antivira ls Hyperosmotics/hypertonics Cyclopleg ics Artificial tear s and
lubricants
Op t ometrist
Optometrists who h ave satisfactorilyco mpl eted a curriculum in general andoc ular pharmaco logy at a college ofop t ometry w ith d ida ctic a n d sup erv isedclinical prog rams approved by thedepartment are elig ible to apply forprescri ptive authority
Optometris t- Diagnostic Agents
Mydriatics Mio tics Cyclop legics Anes thetics
Optometrist - Phase Two
Must be certified fordiagnostic and phase on etherapeutic agents
Completed an additionalone hundred hours ofclinicalt:rain ing in thediagnosis, t:reat:rnent an dmanagement of pa t ientswith glaucoma an d ocu larhype rtension
Success full y passed an ora lor written examina t io naccep ta ble by the boa rd
Alpha -agonists Beta -blockers D irect acting
cholin erg ics
5/22 /201
2
-
7/27/2019 Law Review1
28/28
Physician AssistantNYS Public Health Law : Article 37: 370 2
A dependent practitioner working underth e su pe rvision of a licensed physicianresponsible for the actions of th e P.A.
If de legat ed by physici an, may writem ed ica l o rders an d prescripti ons In pa t ien t : ma y orde r m ed icati o ns , incl uding
C II - V (may require ph y sician 'sco un t ers ignatur e within 24 hours)
Outpatient: ma y prescribe m edicationsincluding CII-V
Obligation to Fill a Prescription
Pharmaci s ts ma y refuse to fill or refill apre scription for go od rea son , including: Drug ou t of sto ck Suspect th e pr escript ion is for ge d Belie v e that th e medi ca ti o n wi ll be harmful to
th e pati e nt Know t h at th e ref i llin g of th e pr escription
vio lates the law
Patient ProfilesPart 63: 63.6b (7)
Mu s t inclu de but not lim ited to ; Na m e, addr ess, ph o ne o f pat ien t Gen der and dat e of birth Kn ow n allergies /drug int erac tions Ch ronic di seases Com pr ehe nsive list of med ications a nd relevant
devices Ot h er in f or mati on reported to th e ph ar maci st
appropriat e for counseli ng the pati en t rega rd ing th euse of pr esc ripti o ns a nd OTC dru gs
5/22 /2013
Who May Dispense?
Pharmaci st acting in th e u sua l course ofprofessional pract ice Registered in d ivid u a lly or employ ed b y a
registe r ed ph a rmacy or regi ste red in s tituti o na lp ractitione r.
Includes those individuals a u th or ize d todi spense under the supervision of aphar mac ist (varies from state to state)
Patie n t Pro fil es
PRESCRIPTIONS
Prospective Drug Review
A prospective drug review is to be do n e prior toth e dispensing of ea ch prescription
Th e review sha ll includ e screening for p ot e nt i a ldrug th er apy pr oblem s due to:
Therapeuti c dupli cat ion Dru g-d isease co nt raind ications Drug-drug interact ions ( incl u ding OTCs) Incorre ct drug dosage or du ration of th e rap y Drug -all ergy in te r actions Clini cal abuse/misuse